



Perforomist® (formoterol fumarate) – First-time generic

- On June 22, 2021, [Teva launched](#) an [AN-rated](#) generic version of Mylan Specialty's [Perforomist \(formoterol fumarate\)](#) inhalation solution.
- Perforomist is approved for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
- According to IQVIA, Perforomist had annual sales of more than \$299 million in the U.S. as of March 2021.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.